Biomea Fusion, INC 10-Q quarterly reports

Biomea Fusion, Inc. filed its Q1 2026 Form 10-Q, detailing a net loss of $12.4 million and a cash balance of $45.1 million, while strategically shifting focus to metabolic diseases.

Biomea Fusion reported a reduced net loss but faces substantial doubt about its ability to continue as a going concern, necessitating further capital raises.

Biomea Fusion, a clinical-stage biotech, reported significant losses and a going concern warning, despite recent capital raises and ongoing clinical trials for diabetes and obesity therapies.

Biomea Fusion reports a net loss for Q1 2025 and expresses concerns about its ability to fund operations beyond Q4 2025 without additional financing.

Biomea Fusion's Q3 2024 report details financial results, including a net loss of $109.1 million for the nine months ended September 30, 2024, and provides updates on their clinical programs, including the lifting of a clinical hold on icovamenib trials.

Biomea Fusion's Q2 2024 report reveals increased R&D spending and a clinical hold on BMF-219 diabetes trials, alongside ongoing oncology program advancements.

Biomea Fusion's first quarter 2024 results show increased operating expenses as the company advances its clinical programs for BMF-219 and BMF-500.